Skip to main navigation Skip to search Skip to main content

Anti-CD30-targeted gold nanoparticles for photothermal therapy of L-428 Hodgkin's cell.

  • Xiaochao Qu
  • , Cuiping Yao
  • , Jing Wang
  • , Zheng Li
  • , Zhenxi Zhang
  • Xidian University

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

Due to the efficient bioconjugation and highly photothermal effect, gold nanoparticles can stain receptor-overexpressing cancer cells through specific targeting of ligands to receptors, strongly absorb specific light and efficiently convert it into heat based on the property of surface plasmon resonance, and then induce the localized protein denaturation and cell death. Two gold nanoparticle-antibody conjugates, gold-BerH2 antibody (anti-CD30 receptor) and gold-ACT1 antibody (anti-CD25-receptor), were synthesized. Gold-BerH2 conjugates can specifically bind to the surface of L-428 Hodgkin's cells, and gold-ACT1 conjugates were used for the control. The gold nanoparticle-induced L-428 cell-killing experiments were implemented with different experimental parameters. At a relatively low concentration of gold and short incubation time, the influence of cytotoxicity of gold on cell viability can be overlooked. Under laser irradiation at suitable power, the high killing efficiency of gold-targeted L-428 cells was achieved, but little damage was done to nontargeted cancer cells. Gold nanoparticle-mediated photothermal therapy provides a relatively safe therapeutic technique for cancer treatment.

Original languageEnglish
Pages (from-to)6095-6103
Number of pages9
JournalInternational Journal of Nanomedicine
Volume7
DOIs
StatePublished - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Anti-CD30-targeted gold nanoparticles for photothermal therapy of L-428 Hodgkin's cell.'. Together they form a unique fingerprint.

Cite this